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Introduction
The Interagency Emergency Health Kit
(IEHK) [1] is a large, pre-packed box
containing medicines and medical supplies
(Table 1). The kit is designed to meet the
expected primary health care (PHC) needs of
persons exposed to acute humanitarian crises
caused, for example, by forced displacement
or major natural disaster such as an earth-
quake, cyclone, or tsunami. Such events often
involve the partial or complete destruction of
locally available medicines. The IEHK aims
to provide sufficient medicines and supplies
for medical care for a population of 10,000
people—located in one geographical area or
place—for 3 months. The next version of the
IEHK will be the fourth edition of the one
originally developed three decades ago [2,3].
While data on this new IEHK are not yet
available, the third edition came in a very
heavy, large box (1,045 kg, 4.6 m
3)c o n t a i n -
ing ten basic kits and one supplementary kit
[4]. The IEHK is held in stock by major
suppliers of generic medicines, most of whom
ship it within 48 hours after being ordered by
an aid agency (Figure 1).
The IEHK has become a core feature of
international emergency response when-
ever medical facilities and pharmacies
have been destroyed or populations have
been displaced. Medical relief agencies
tend to immediately allocate emergency
funds to procure kits. These kits typically
play a major role very early in sudden-
onset emergencies when the exact medical
needs of the population, the health services
situation, and human resource capacities
are largely unknown. Once local needs
and resources have been assessed, stan-
dard orders of IEHKs tend to be
replaced—as they should—with situation-
specific orders of medicines and supplies.
The IEHK ensures continuity in the
supply of medicines, most of which are life-
saving. It addresses at least three emergency-
relief management challenges: (a) managing
the procurement, distribution, and logistics of
supplies in an efficient manner; (b) focusing
the good intent of donors of medicines and
medical devices on a small variety of essential
products rather than flooding systems with a
large variety of unknown products, including
expensive, non-essential, expired, or poorly
labelled ones; and (c) harmonizing use of
different medicines by different organizations
for the same conditions across the health
system [5,6].
The IEHK is not a mini-pharmacy. Its
p u r p o s ei st oa l l o wf o rar e s p o n s ei nt h ea c u t e
phase of emergencies before any needs
assessment results becomes available. Given
that its size is limited to allow for easy
transport, the kit involves a compromise,
providing a limited range and number of
medicines that are considered priority to
meet the needs of populations with disrupted
medical facilities. All medicines in the kit are
on the WHO Model List of Essential
M e d i c i n e s[ 7 ]( W H OM o d e lL i s t ) .T h i si sa
prioritized list of over 350 medicines selected
through a transparent, rigorous review of the
evidence that considers the public health
relevance, efficacy, safety, and cost-effective-
ness of different medicines. The WHO
M o d e lL i s ti su s e db ym a n yc o u n t r i e sa sa
basis for deciding what medicines should be
on their national list of essential medicines,
which guides (amongst other things) procure-
ment and supply of medicines for local PHC
services. The IEHK, however, can only
include only a fraction of the medicines on
the WHO Model List. The 2011 version of
the IEHK will contain 73 medicines.
Psychotropic Medicines in the
IEHK
Medical care for peoplewith severe mental
or neurological disorders has, historically, not
been a priority in humanitarian crises, but
this is changing [8]. One major impetus for
change has been the Inter-Agency Standing
Committee (IASC) Guidelines on Mental Health
and Psychosocial Support in Emergency Settings [9],
which was developed through an extensive
consultation process. The Guidelines were
released by a committee of United Nations
(UN) and non-UN international humanitar-
ian agencies responsible for humanitarian
policy according to UN General Assembly
resolution 46/182. The Guidelines describe
minimum responses during emergencies and
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tions for the population at large as well as
psychological first aid for people experiencing
acute distress. In addition, these IASC
guidelines emphasize the protection of and
care for people with severe mental disorders
as a priority in acute emergencies.
The IEHK has been inadequate with
respect to psychotropics. For example, the
third (2006) edition included only three
psychotropic medicines (chlorpromazine in-
jections, diazepam injections, phenobarbital
tablets), which do not cover first-line treat-
ment of depression and psychosis. The IASC
Guidelines stipulate that the minimum
provision of medicines in emergency health
kits should include—in tablet form—at least
one anti-depressant, one anxiolytic, one anti-
psychotic, one anti-Parkinsonian (to deal with
extra-pyramidal side effects of anti-psychotic
medicines), and one anti-epileptic medicine.
In 2009, the authors submitted an inter-
agency proposal to suggest changes to the
psychotherapeutic and antiepileptic medi-
cines classesof the IEHK. This proposal was
shaped by two considerations. First, given
that the IEHK is meant to be a subset of
medicines of the WHO Model List, the
proposal was limited to selecting from the
few psychotropic medicines on that list
(Table 2). Second, given that the previous
IEHK only had 67 medicines to address all
priority health conditions relevant to PHC
in emergency settings, the selection of
additional medicines needed to be propor-
tionate: one medicine for each of the classes
of psychotropic medicines. The proposal—
described in this article—was approved by
the independent, inter-agencyReview Com-
Summary Points
N The Interagency Emergency Health Kit is a box with medicines and medical
supplies designed to meet the expected primary health care needs of people
exposed to major humanitarian emergencies.
N Previous editions of the kit have been inadequate to help people with severe
mental or neurological disorders.
N The challenge to be addressed was to propose the inclusion of one medicine
for each of five classes of psychotropic medicines.
N Amitriptyline (tablets), haloperidol (tablets and injections), diazepam (tablets
and injections), biperiden (tablets), and phenobarbital (tablets) will be included
in the next edition of the kit.
N A fundamental inequity has been addressed by ensuring that the availability of
medicines for people with severe mental and neurological disorders will be on a
par with that for other medical disorders in emergencies.
Figure 1. Cyclone Nargis response 2008: Interagency Emergency Health Kits en route to Myanmar. Photo credit: Fred Urlep, WHO.
doi:10.1371/journal.pmed.1001030.g001
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gency Health Kit, which consists of public
health experts overseeing the IEHK update.
Medicines from each of the aforementioned
five classes of psychotropic medicines will be
included in the next edition of the IEHK.
Choice of Anti-Depressant
Fluoxetine and amitriptyline are the
only anti-depressant medicines on the
WHO Model List. After review of the
advantages and disadvantages (Table 3) of
these two similarly effective medicines
[10,11], amitriptyline was selected. The
overriding consideration was the need to
be consistent with what is most likely to be
available currently in most low-income
country PHC systems to maximize conti-
nuity of care and build on local PHC
capacities. Compared to fluoxetine, ami-
triptyline is more widely available in PHC
systems in emergency-prone Africa [12].
Selecting amitriptyline is consistent with
the IASC Guidelines, which recommends the
use of medicines that are on the country’s
essential medicines list [8]. Fluoxetine was
only added to the WHO Model List in 2007.
We expect that in future years fluoxetine will
slowly be added to many countries’ national
list of essential medicines and accordingly will
become widely available in Africa as well. We
envision that future updates of the kit —
possibly as early as the fifth edition in 2015—
will involve replacing amitriptyline with
fluoxetine, because fluoxetine is easier to
prescribe and is more suitable for a broader
range of age groups (e.g., from adolescence to
old age). Of note, the evidence on these two
medicines for use in post-traumatic stress
disorder is inconclusive [13] and did not
influence the selection.
Choice of Anxiolytic
A small supply of diazepam tablets will be
added to the kit. The only anxiolytics on the
WHO Model List are diazepam (in tablet
and injectable form) and lorazepam (in
injectable form). People presenting with
normal (non-pathological), acute anxiety are
numerous in the early phases of all emergen-
cies. Non-pharmacological measures (e.g.,
psychological first aid) should be used.
Psychological first aid involves basic, non-
intrusive pragmatic care with a focus on
listening but not forcing talk; assessing needs
and concerns; ensuring that basic needs are
met; encouraging social support from signif-
icant others; and protecting from further
harm [9]. Anxiolytics in the form of
benzodiazepines may slow down recovery
from traumatic stress [14], can produce
dependence, and tend to be prescribed
indiscriminately in many emergencies. While
precautions should be taken to prevent the
routine prescription of benzodiazepines to
people experiencing distress in emergencies
[15], there are occasions when anxiolytics are
indicated. For example, they are appropriate
in cases of severe agitation or sleeplessness
that interfere with a person’s ability to address
their own and their family’s survival needs,
and that do not respond to non-pharmaco-
Table 1. Psychotropics in the next edition of the Interagency Emergency Health Kit [1].
Type of Product
Variety Available in the Kit within Each Type of
Product
Medicines
Anaesthetics 2
Analgesics 4
Antiallergics 3
Antidotes 2
Anticonvulsants/anti-epileptics 3
a
Anti-infective medicines 11
Malaria module 5
Medicines affecting the blood 2
Cardiovascular medicines 3
Dermatological medicines 6
Disinfectants and antiseptics 2
Diuretics 2
Gastrointestinal medicines 3
Oxytocics 2
Psychotherapeutic medicines 5
b
Respiratory tract, medicines acting on 2
Solutions correcting water, electrolyte and acid-base disturbances 5
Vitamins 2
PEP module 9
Clinical guidelines 3
Medical devices, renewable 48
Medical devices, equipment 36
Stationary 6
aThe three anti-convulsants are phenobarbital (1,000 50-mg tablets), diazepam (200 injections, 5 mg/ml; 2 ml/ampoule), and magnesium sulfate (40 injections; 500
mg/ml; 10 ml/ampoule).
bThe five psychotherapeutic medicines are amitriptyline (4,000 25-mg tablets); biperiden (400 2-mg tablets), diazepam (240 5-mg tablets), haloperidol (1,300 5-mg
tablets), and haloperidol (20 injections; 5 mg/ml; 1 ml/ampoule).
doi:10.1371/journal.pmed.1001030.t001
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injectable diazepam in previous editions of
the kit has meant that on many occasions
acutely anxious individuals were treated with
injections of diazepam. This is not the first-
line route of administration in anxiety
reactions, and this encourages frequent
returns to the already overburdened emer-
gency health care provider. When combined
with psychological first aid and culturally
relevant relaxation methods, dispensing a few
days of diazepam tablets can be humane and
appropriate to lessen agitation and restore
sufficient sleep to help a severely distressed
person through a crisis. Injectable diazepam
will be kept in the kit for the management of
status epilepticus.
Choice of Anti-Psychotic
Injectable chlorpromazine—which was in
the previous edition of the kit—will be
replaced with haloperidol in both injectable
and tablet form. Anti-psychotic tablets will
be added for a number of reasons. Although
injections can be used, oral administration is
preferred in chronic psychosis, which may
occur throughout an extended humanitari-
an emergency. Tablets also have the
advantage that they can be provided by
family members after prescription by very
busy health staff. Oral haloperidol is pre-
ferred to oral chlorpromazine because,
despite similar efficacy, randomized evi-
Table 2. The WHO Model List of Essential Medicines and the Interagency Emergency Health Kit (IEHK).
Inclusion in the WHO Model List of Essential Medicines [7]
Inclusion in the Next Edition of the
Interagency Emergency Health Kit [1]
Psychotherapeutic medicines
Chlorpromazine
a Injection: 25 mg (hydrochloride)/ml in 2 ml ampoule; oral liquid: 25 mg
(hydrochloride)/5 ml; tablet: 100 mg (hydrochloride)
No
Fluphenazine
a Injection: 25 mg (decanoateac or enantate) in 1 ml ampoule No
Haloperidol
a Injection: 5 mg in 1 ml ampoule; tablet: 2 mg; 5 mg Yes (5 mg in 1-ml ampoule injection and 5-
mg tablets)
Amitriptyline
a Tablet: 25 mg (hydrochloride). Yes
Fluoxetine Solid oral dosage form: 20 mg (present as hydrochloride) No
Carbamazepine Tablet (scored): 100 mg; 200 mg No
Lithium carbonate Solid oral dosage form: 300 mg No
Valproic acid Tablet (enteric coated): 2000 mg; 500 mg (sodium valproate) No
Diazepam
a Tablet (scored): 2 mg; 5 mg Yes (5-mg tablets)
Clomipramine Capsule: 10 mg; 25 mg (hydrochloride) No
Antiparkinsonism medicines (to deal with potential extra-pyramidal side effects of anti-psychotics)
Biperiden Injection: 5 mg (lactate) in 1 ml ampoule; tablet: 2 mg (hydrochloride) Yes (2-mg tablets)
Anticonvulsants/antiepileptics
Carbamazepine Oral liquid: 100 mg/5 ml; tablet (chewable): 100 mg; 200 mg; tablet (scored):
100 mg; 200 mg
No
Diazepam Gel or rectal solution: 5 mg/ml in 0.5-ml, 2-ml, and 4-ml tubes Yes (5 mg/ml in 2-ml tube)
Lorazepam
a Parenteral formulation: 2 mg/ml in 1 ml ampoule; 4 mg/ml in 1 ml ampoule No
Phenobarbital Injection: 200 mg/ml (phenobarbital sodium); oral liquid: 15 mg/5 ml (as
phenobarbital or phenobarbital sodium); tablet: 15–100 mg (phenobarbital)
Yes (50-mg tablets)
Phenotyn Capsule: 25 mg; 50 mg; 100 mg (sodium salt); injection: 50 mg/ml in 5-ml vial
(sodium salt); oral liquid: 25–30 mg/5 ml; tablet: 25 mg; 50 mg; 100 mg
(sodium salt); tablet (chewable): 50 mg
No
Valproic acid Oral liquid: 200 mg/5 ml; tablet (crushable): 100 mg; tablet (enteric coated):
200 mg; 500 mg (sodium valproate)
No
aIndicates that the medicine represents a pharmacological class (similar clinical performance).
doi:10.1371/journal.pmed.1001030.t002
Table 3. Advantages and disadvantages of including fluoxetine versus amitriptyline in the Interagency Emergency Health Kit
(IEHK).
Advantages Disadvantages
Fluoxetine 1. Generally safer [18]
2. Slightly better adherence [26]
3. Can also be used in adolescents [18]
1. Can increase anxiety, which already is common in emergencies [18]
2. Substantially more expensive and less cost-effective in many
countries [26]
Amitriptyline 1. Most available anti-depressant in low-income countries [12]
2. Sedative effect (less tendency to also prescribe benzodiazepines)
3. Also analgesic (relevant in emergencies involving mass casualties)
1. More difficult to prescribe: medical examination is important to
avoid rare but serious side effects (cardiac events) [18]
2. Lower tolerance in older people [18]
doi:10.1371/journal.pmed.1001030.t003
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with better acceptability rates [16]. With
respect to injectable anti-psychotics, Nation-
al Institute for Health and Clinical Excel-
lence (NICE) Guidelines recommend
against rapid tranquillization using chlor-
promazine, highlighting a number of side
effects including acting as a local irritant if
given intramuscularly [17]. Accordingly,
chlorpromazine injections will be replaced
with haloperidol tablets and injections.
Choice of Anti-Parkisoninan
Anti-cholinergic medicines need to be
available to counteract movement disorders
(such as Parkinsonism and acute dystonia)
that can occur as side effects of anti-psychotic
medicines [18]. A Cochrane review [19]
reported that 33% of patients on haloperidol
develop movement disorders and need anti-
cholinergic medication. Biperiden and levo-
dopa/carbidopa are the two anti-Parkinso-
nian medicines on the WHO Model List.
Levodopa/carbidopa is generally not used in
mental health to treat the side effects of anti-
psychotics, so biperiden was suggested.
Choice of Anti-Epileptic
Phenobarbital continues to be in the kit,
because it is by far the most commonly
available anti-epileptic medicine in low-
income countries [20], by far the least
expensive, and by far the most cost-effective
[21]. Tolerability of phenobarbital tends to
be adequate [22], and it is promoted through
the Global Campaign Against Epilepsy by
WHO, the International League against
Epilepsy, and the International Bureau for
Epilepsy. However, the 100-mg tablet in the
previous kit is too large for the treatment of
children (even when one breaks the tablet), so
the tablet weight will be reduced to 50 mg to
make it available for children.
There is a caveat to the inclusion of
phenobarbital and diazepam in the kit,
and that is that these are controlled
medicines requiring import authorization
from national authorities [23]. This causes
significant delays in delivery of the kit, as
national authorities tend to be over-
whelmed in emergencies. To address this
challenge, suppliers of the IEHK tend to
offer the option of buying the kit without
controlled psychotropics or narcotics [4].
While some offer to substitute narcotics
with tramadol (an analgesic that is not
controlled), they do not offer substitutes for
phenobarbital and diazepam. Although
we are not aware of a good non-controlled
alternative medicine to diazepam, drug
suppliers may consider substituting phe-
nobarbital with carbamazepine. The latter
is much more expensive, but it is an
effective anti-convulsant that is on the
essential medicines list of almost all
countries [20]. Carbamazepine should be
importable given that it is not controlled.
Discussion
The changes to the IEHK described in
this article have addressed a fundamental
inequity. In emergencies, PHC profession-
als will now be in a position to provide
medical treatment to people with severe
mental or neurological disorders on a par
with treatment for other medical condi-
tions, because psychotropic medicines will
be available in emergencies.
Some observers may argue that the
IEHK should be limited to life-saving
medicines, but such reasoning is not in line
with current thinking. For example, the
influential Sphere Project [24] promotes the
principle of survival with dignity through its
widely endorsed handbook. Although many
people with severe mental disorders tend to
not experience dignified life conditions even
before a conflict or other disaster strikes
(e.g., in terms of housing conditions or work
opportunities), their life conditions tend to
worsen dramatically during emergencies.
When left untreated, these disorders put
people at substantial risk of death in the midst
of an emergency [8]. People with psychosis
have been known to be shot in conflict
situations because of not comprehending
instructions by soldiers. Alternatively, many
have been abandoned by family members
when there is population movement. Parents
with severe depression in emergencies have
neglected to take care of themselves or feed
and provide care to their children. Also,
people who were treated with anti-epileptics
before the emergency face a fatal risk if there
is a sudden discontinuation of supply of anti-
epileptics due to the emergency. Finally,
mental and neurological disorders are asso-
ciated with elevated mortality rates [25].
Many specialists in psychiatry and neurol-
ogy will likely argue that the inclusion of just
one medicine of each of the classes of
psychotropic medicines is insufficient. They
may experience it as unacceptable that the
vast arsenal of medicines available in modern
specialist care is reduced to a handful of first-
generation drugs. However, the IEHK has to
beli m it e dinsiz et ob efe as ib lym ad ea v ai la ble
during acute emergencies.
In humanitarian emergencies that affect
large numbers of people, it is necessary to
apply a population-wide perspective to use all
available means to address the health status of
the maximum number of people. This
requires priority setting, which involves
making difficult choices. Including one
medicine from each of five classes of
psychotropic medicines in the IEHK has
involved tough priority setting but has been a
major step towards the agreed goal of
providing minimum care for people with
severe mental and neurological disorders in
emergencies [9].
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